For 2018, CIBC World Markets is recommending investors hold a basket of healthcare stocks that include a combination of more speculative small and midcap companies with selected large caps.Read More
BTIG downgraded AtriCure (NASDAQ:ATRC) to “neutral,” citing a recent share price rally coupled with an unchanged outlook after the company’s Q4 report. The stock closed at $18.96 on March 3.Read More
Scotiabank initiated coverage of Novadaq Technologies (NASDAQ:NVDQ; TSX:NDQ) with a “sector outperform” rating and a one-year price target of $18. The stock closed at $11.43 on Tuesday.
Analyst Alan Ridgeway writes that at a multiple of eight times estimated 2017 sales, “Novadaq would trade at a premium to peers, which is justified, in our opinion, because we believe it will break even in roughly 12 months and has the potential to grow more than 30% annually through 2020.”Read More
Stifel has raised its price target for Cynosure (NASDAQ:CYNO) to $50 from $44, reflecting revised estimates and an increased sales multiple due to the company’s higher growth rate. The stock closed at $42 on Monday.
Cynosure is a medical device company focused on designing, manufacturing, and marketing energy-based systems primarily for minimally invasive and non-invasive aesthetic procedures.Read More